New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Best practices for safe subretinal delivery of gene therapy were presented at the Retina ...

To assess the efficacy of small-gauge vitrectomy with subretinal recombinant tissue plasminogen activator (rtPA) and ranibizumab for submacular haemorrhages secondary to neovascular age-related ...

Please provide your email address to receive an email when new articles are posted on . Pars plana vitrectomy with subretinal tissue plasminogen activator injection led to significant vision ...

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the first surgery using its proprietary Orbit™ Subretinal Delivery System ...

In experiments with rats, pigs and monkeys, Johns Hopkins Medicine researchers have developed a way to deliver sight-saving gene therapy to the retina. If proved safe and effective in humans, the ...

“Currently, there is a lack of evidence-based research and rigorous guidelines for the management of patients with SMH secondary to nAMD [neovascular AMD],” said Dr. Gabrielle, who is based at the ...

PDE6A-associated RP, a rare form of inherited retinal disease (IRD), is characterized by nyctalopia, visual field defects, and significant loss of visual acuity (VA). The disease primarily affects the ...

In experiments with rats, pigs and monkeys, researchers have developed a way to deliver sight-saving gene therapy to the retina. If proved safe and effective in humans, the technique could provide a ...

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced positive interim safety, protein expression and biomarker ...